Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04680637
Study type Interventional
Source Amgen
Contact
Status Terminated
Phase Phase 2
Start date May 6, 2021
Completion date May 22, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04931563 - Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE) Phase 3
Completed NCT02446912 - Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Phase 3
Completed NCT02794285 - Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Phase 3
Completed NCT02446899 - Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Phase 3